Immutep Ltd (IMMP) FinancialsIMMPImmutep Ltd

Immutep Ltd (IMMP) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Cancer Immunotherapy, accounting for 51.4% of total sales, equivalent to AUD 2.11M. Another important revenue stream is Unallocated. Understanding this composition is critical for investors evaluating how IMMP navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Immutep Ltd maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1170.97%, while the net margin is -1095.35%. These profitability ratios, combined with a Return on Equity (ROE) of -61.85%, provide a clear picture of how effectively IMMP converts its operational activities into shareholder value.

In the context of the broader market, IMMP competes directly with industry leaders such as ELTX and LONA. With a market capitalization of $56.15M, it holds a significant position in the sector. When comparing efficiency, IMMP's gross margin of 100.00% stands against ELTX's N/A and LONA's N/A. Such benchmarking helps identify whether Immutep Ltd is trading at a premium or discount relative to its financial performance.

The forward P/E ratio is 7.1327, indicating potential value, but the negative P/E ratio of -0.675731 raises concerns about profitability. The price-to-book ratio is 0.56774, suggesting the stock may be undervalued relative to its assets.